Number of Patients, Male	11
Number of Patients, Female	10
Stage	Unresectable locally advanced or metastatic well‐differentiated G1 or 2 (Ki‐67 ≤20%)
Age	Median (range): 57.4 (37.4–73.4)
Number of Prior Systemic Therapies	Median (range): 3 (1.0–10.0)
Performance Status: ECOG	0 — 9 1 — 11 2 — 3 — Unknown — 1
Other	Patients eligible for enrollment were 18 years of age or older and had histologically or cytologically diagnosed, unresectable locally advanced, or metastatic well‐differentiated G1 or 2 pNET (Ki‐67 ≤20%), which had progressed on at least one line of prior systemic therapy. Patients previously treated with somatostatin analogs (SSAs), chemotherapy, antiangiogenics, mTOR inhibitors, radionuclides, or interferon were permitted providing that toxicity had resolved to grade ≤1 and 4 weeks had passed after last administration. Concomitant treatment with SSAs was allowed. Additionally, eligible patients had documented progression of disease by CT scan, magnetic resonance imaging, or somatostatin receptor scintigraphy within 12 months of study entry; ECOG performance status <2; and a life expectancy >12 weeks.
Cancer Types or Histologic Subtypes	Pancreatic neuroendocrine